Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

NCT04526574 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1796

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Disease

Interventions

BIOLOGICAL: Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
OTHER: Saline
BIOLOGICAL: Influenza vaccine

Sponsor

Pfizer